Possible relationships between plasma carbamazepine-10, 11-epoxide levels and antimanic efficacy and side effects in patients with schizoaffective disorder

Human Psychopharmacology

Volumn 15, Issue 4, 2000, Pages 237-240

  Yoshimura, Reiji ^a   Nakamura, Jun ^a   Eto, Seiji ^a   Ueda, Nobuhisa ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Carbamazepine; Carbamazepine 10, 11 epoxide; Carbamazepine 10,11 diol; Schizoaffective disorder

Indexed keywords

CARBAMAZEPINE; DRUG METABOLITE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOIDISM; SIDE EFFECT;

EID: 0034094494     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1077(200006)15:4<237::AID-HUP160>3.0.CO;2-5     Document Type: Article

References (14)

1. Denicoff KD, Meglathery SB, Post RM, Tandeciarz SI. 1994. Efficacy of carbamazepine compares with other agents: a clinical practice survey. J Clin Psychiat 55: 70-76.
2. Eto S, Tanaka N, Noda H, Noda A. 1995. 9-hydroxymethyl-10-carbamoylacridan in human serum is one of the major metabolites of carbamazepine. Biol Pharmaceut Bull 18: 325-330.
3. Faigle JW, Feldman KF. 1982. Carbamazepine: biotransformation. In Antiepileptic drugs, 2nd edn, Pendy JK, Pippenger CE, Hessie DJ (eds). Raven Press: New York; 483-495.
4. Monaco F, Riccio A, Benna P, Covacich A, Durelli L, Furlan PM, Gilli M, Mutani R, Troni W, Gerna M, Morselli PL. 1976. Further observation on carbamazepine plasma levels in epileptic patients: relationships with therapeutic and side effects. Neurology 26: 936-943.
5. Post RM. 1982. Carbamazepine's acute and prophylactic effects in manic and depressive illness: an update. Int Drug Therapy News 17: 5-10.
6. Post RM. 1987. Mechanism of action of carbamazepine and related anticonvulsants in affective illness. In Psychopharmacology, The Third Generation of Progress, Melzer HY (ed.). Raven Press: New York; 567-575.
7. Post RM, Uhde TW, Ballenger JC, Chatterji DC, Greene RF, Burnney Jr WE. 1983. Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Arch Gen Psychiat 40: 673-676.
8. Post RM, Rubinow DR, Uhde TW, Ballenger JC, Lake CR, Linnoila M, Jimerson DC, Reus V. 1985. Effects of carbamazepine on noradrenergic mechanisms in affectively ill patients. Psychopharmacology 87: 59-63.
9. Siever LJ. 1987. Role of noradrenergic mechanisms in the etiology of the affective disorders. In Psychopharmacology, The Third Generation of Progress, Melzer HY (ed.). Raven Press: New York; 493-504.
10. Tomson T, Bertilsson L. 1984. Potent therapeutic effect of carbamazepine-10,11-epoxide in trigeminal neuralgia. Arch Neurol 41: 598-601.
11. Tomson T, Tybring G, Bertilsson L, Ekbom K, Rane A. 1980. Carbamazepine therapy in trigeminal neuralgia: clinical effects in relation to plasma concentration. Arch Neurol 37: 699-703.
12. Tomson T, Tybring G, Bertilsson L. 1983. Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. Clin Pharmacol Therapeut 33: 58-65.
13. Yoshimura R, Yanagihara N, Terao T, Minami K, Abe K, Izumi F. 1995. Inhibition by carbamazepine of various ion channels-mediated catecholamines secretion in cultured adrenal medullary cells. Naunyn-Schmiedeberg's Arch Pharmacol 352: 297-303.
14. Yoshimura R, Yanagihara N, Terao T, Minami K, Toyohira Y, Ueno S, Uezono Y, Abe K, Izumi F. 1998. An active metabolite of carbamazepine, carbamazepine-10,11-epoxide, inhibits ion channel-mediated catecholamine secretion in cultured bovine adrenal medullary cells. Psychopharmacology 135: 368-373.